Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 7/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006838 | 1.00 | ESR1 (0.47) | ESR1ESR2SLC7A5KDM4EF13A1 | |
| SCHEMBL1007574 | 1.00 | ESR1 (0.47) | ESR1ESR2SLC7A5KDM4EF13A1 | |
| SCHEMBL2269090 | 0.87 | ACACB (0.57) | ACACB | |
| SCHEMBL2269225 | 0.85 | ACACB (0.58) | ACACB | |
| SCHEMBL2267795 | 0.85 | ACACB (0.44) | ACACB | |
| SCHEMBL2268001 | 0.85 | ACACB (0.58) | ACACB | |
| SCHEMBL2843211 | 0.85 | CTRB1 (0.57) | SLC7A5ACACB | |
| SCHEMBL334424 | 0.85 | CTRB1 (0.57) | SLC7A5ACACB | |
| SCHEMBL334301 | 0.85 | CTRB1 (0.57) | SLC7A5ACACB | |
| SCHEMBL6438932 | 0.84 | GAA (0.43) | ESR1ESR2ACACBFOLH1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | claimed |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20110118172-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | claimed |
| EP-2314609-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | claimed |
| JP-4653840-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-10 | — | — | US | claimed |
| EP-2277900-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | claimed |
| US-20090298765-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | US | claimed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | claimed |
| US-20090215700-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-27 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | claimed |
| WO-2007072997-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | WO | claimed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | claimed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215700-A1 | Metastin derivatives and use thereof | SHBG, GNRHR, INHA | ESR1 318/4885ESR2 234/4885SLC7A5 1205/4885 |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | ESR1 250/4885ESR2 270/4885SLC7A5 3325/4885 |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | ESR1 318/4885ESR2 234/4885SLC7A5 1205/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | ESR1 250/4885ESR2 270/4885SLC7A5 3325/4885 |
| US-20110118172-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, INHA | ESR1 309/4885ESR2 343/4885SLC7A5 1090/4885 |
| US-20090298765-A1 | Metastin derivatives and use thereof | GNRHR, SHBG, MEN1 | ESR1 287/4885ESR2 209/4885SLC7A5 2865/4885 |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, LHCGR | ESR1 359/4885ESR2 312/4885SLC7A5 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.